Induction of ischemic tolerance as a promising treatment against diabetic retinopathy

Ruth E. Rosenstein, Diego C. Fernandez,

1 Laboratory of Retinal Neurochemistry and Experimental Ophthalmology, Department of Human Biochemistry, School of Medicine/CEFyBO, University of Buenos Aires/CONICET, Buenos Aires, Argentina

2 Present address: Johns Hopkins University, Department of Biology, Baltimore, MD, USA

Induction of ischemic tolerance as a promising treatment against diabetic retinopathy

Ruth E. Rosenstein1, Diego C. Fernandez1,2

1 Laboratory of Retinal Neurochemistry and Experimental Ophthalmology, Department of Human Biochemistry, School of Medicine/CEFyBO, University of Buenos Aires/CONICET, Buenos Aires, Argentina

2 Present address: Johns Hopkins University, Department of Biology, Baltimore, MD, USA

Diabetic retinopathy is a leading cause of acquired blindness, and it is the most common ischemic disorder of the retina. Available treatments are not very effective. Efforts to inhibit diabetic retinopathy have focused either on highly speci fi c therapeutic approaches for pharmacologic targets or using genetic approaches to change expression of certain enzymes. However, it might be wise to choose innovative treatment modalities that act by multiple potential mechanisms. The resistance to ischemic injury, or ischemic tolerance, can be transiently induced by prior exposure to a non-injurious preconditioning stimulus. A complete functional and histologic protection against retinal ischemic damage can be achieved by previous preconditioning with non-damaging ischemia. In this review, we will discuss evidence that supports that ischemic conditioning could help avert the dreaded consequences that results from retinal diabetic damage.

diabetic retinopathy; ischemic tolerance; retina; ischemic injury; ischemic conditioning

Rosenstein RE, Fernandez DC. Induction of ischemic tolerance as a promising treatment against diabetic retinopathy. Neural Regen Res. 2014;9(17)：1581-1584.

Diabetic retinopathy

About 380 million people across the globe are estimated to have diabetes, and its prevalence is expected to drastically increase in the near future (Shi et al., 2014). One of the most serious complications of diabetes is diabetic retinopathy (DR) (Szabad fi et al., 2014). Nearly all individuals with type 1 diabetes mellitus (T1DM), and more than 60% of individuals with type 2 diabetes mellitus (T2DM) have some degree of retinopathy after 20 years of diabetes (Robinson et al., 2012). DR is a leading cause of reduced visual acuity and acquired blindness. In inadequately controlled patients, the retinal microvasculature is constantly exposed to high glucose levels, which results in vascular damage and leakage, edema, capillary basement membrane thickening, neovascularization, hemorrhage, ischemia, and neuroglial alterations (Barber et al., 2011, Kowluru and Chan, 2007). Despite many differences between T1DM and T2DM, both forms of diabetes will lead to a similar retinopathy (Szabad fi et al., 2014). Current treatments for DR such as laser photocoagulation, corticosteroids, or anti-vascular endothelial growth factor (VEGF) agents are indicated for advanced DR, but have adverse effects. Therefore, new therapeutic treatments for DR are needed. In experimental studies, efforts to inhibit DR have focused either on highly speci fi c therapeutic approaches for pharmacologic targets (Du et al., 2010) or using genetic approaches to change expression of certain enzymes (Zheng et al., 2007). Alternatively, identi fi cation of innovative treatment modalities that act by multiple potential mechanisms would be necessary. In this review, we will discuss evidence that supports that ischemic conditioning might pave the way for finding novel therapeutic strategies against retinal diabetic damage.

Ischemic conditioning

The resistance to ischemic injury, or ischemic tolerance, can be transiently induced by prior exposure to a non-injurious preconditioning stimulus. Ischemic preconditioning (IPC) itself initiates several adaptive reactions that lead to the establishment of what might be described as a “latent” protective phenotype; priming the tissue for the actual injurious ischemic event (Gidday, 2006). The fi rst landmark paper on cardiac preconditioning in dogs by brief coronary ischemia was published in 1986 (Murry et al., 1986). Since then, many studies have strongly demonstrated that preconditioning stimuli trigger ischemic tolerance in different tissues (Gidday, 2006).

Ischemia is one of the key factors determining the pathophysiology of many retinal diseases, such as DR, glaucoma, and age-related macular degeneration, among others. Ischemic retinopathy develops when retinal blood flow is insuf fi cient to match the metabolic needs of the retina (one of the highest oxygen consuming tissues), and induces irreversible morphologic and functional changes that result in blindness. Studies have focused on the ability of exogenous agents to treat retinal ischemic damage, but thus far, none of these strategies is completely effective. Roth et al. (1998) first demonstrated a complete functional and histologic protection against retinal ischemic damage by previous pre-conditioning with non-damaging ischemia (5-minute ischemia). According to these authors, IPC is more effective in decreasing retinal ischemic injury than nearly any previously reported pharmacologic treatment. However, despite the robust neuroprotection induced by IPC, its use as a clinical strategy is limited because the onset of retinal ischemia is unpredictable, in contrast to the onset of reperfusion, which may be more predictable. Another endogenous form of protection in which a short series of repetitive cycles of brief ischemia-reperfusion were applied immediately at the onset of reperfusion, termed postconditioning (PostC), has been reported. PostC reduces myocardial injury to an extent comparable to that of IPC (Zhao et al., 2003). Other groups have con fi rmed the effectiveness of PostC in the central nervous system (Pignataro et al., 2008; Wang et al., 2008). We have shown that repetitive cycles of briefly interrupted reperfusion performed at the onset of full reperfusion, or even one 7-minute ischemia pulse applied 5 minutes after ischemia (PostC) induces a complete recovery from retinal I/R damage which is effective even when applied 60 minutes after the onset of reperfusion (Fernandez et al., 2009). The effectiveness of ischemic tolerance against acute ischemic events suggests that these strategies could contribute to the discovery of new therapeutic alternatives for chronic ischemic diseases, such as DR.

Ischemic conditioning and diabetic retinopathy

Since available treatments for DR are not completely effective, it is imperative to develop better approaches for its prevention and treatment. Unraveling which is the most critical mechanism to be targeted by new therapeutic strategies, is unlikely to be achieved in studies limited to the clinically observable retinal changes in human DR. Far more detailed and invasive studies are required, preferably in readily available animal models. The streptozotocin (STZ)-induced diabetes in rats shows many of the retinal alterations observed in human DR associated with T1DM (Wei et al., 2003). We have shown that the combination of diet-induced insulin resistance and a slight secretory impairment resulting from a low-dose STZ treatment mimics some features of human T2DM at its initial stages, and provokes significant retinal alterations (Salido et al., 2012). Based on the highly effective protection induced by IPC and PostC against an acute ischemic episode, and considering that DR is the most common ischemic disorder of the retina (Stitt et al., 2011), the effect of ischemic tolerance on retinal damage induced by both experimental T1DM and T2DM was analyzed. The results obtained are summarized below.

Ischemic tolerance on diabetic retinopathy associated to T1DM

T1DM was induced by an intraperitoneal injection of STZ, and ischemic tolerance was induced by increasing intraocular pressure (IOP) to 120 mmHg for 5 minutes; this maneuver started 3 days after STZ injection and was weekly repeated in one eye, while the contralateral eye was submitted to a sham procedure. Weekly ischemia pulses, which show no effectper se, prevent retinal alterations induced by experimental diabetes (Fernandez et al., 2011). It is well known that human diabetes induces significant alterations in the electroretinogram (ERG) and oscillatory potentials (OPs) (Coupland, 1987; Holopigian et al., 1992; Lovasik and Kergoat, 1993). In agreement, a signi fi cant and progressive ERG dysfunction is observed in eyes from rats injected with STZ, whereas weekly ischemia pulses prevent the decrease in ERG a- and b-wave, and OP amplitude induced by experimental diabetes (Fernandez et al., 2011).

Evans blue has been widely used for blood-retinal barrier (BRB) studies in several species (Ma et al., 1996; Zhang et al., 2005). Since intravenously injected Evans blue binds irreversibly to serum albumin, its distribution re fl ects albumin exchange between the intra- and extravascular compartments. In diabetic retinas submitted to a sham procedure, extravasated Evans blue is evident, whereas ischemia pulses prevent the effect of diabetes on BRB integrity. Astrocytes are closely associated with retinal vessels (Schnitzer, 1988), helping to maintain their integrity (Zhang and Stone, 1997), and increasing the vascular endothelium barrier properties (Gardner, 1995). Astrocyte dysfunction plays a pivotal role in inner BRB breakdown, resulting in the production of vasogenic edema (Chan-Ling and Stone, 1992; Gardner et al., 1997). Experimental diabetes induces a decrease in astrocyte glial fi brillary acid protein (GFAP) immunoreactivity, which is restored by ischemia pulses. A reduction in retinal astrocyte GFAP expression during diabetes may be linked to a reduced ability to maintain BRB characteristics in endothelial cells (Barber et al., 2000). Thus, changes in GFAP immunoreactivity could account for Evans blue leakage in diabetic eyes and its prevention by ischemic tolerance. The BRB plays an important role in the homeostatic regulation of the retinal microenvironment. Disruption of the BRB associated with increased vascular permeability results in edema and tissue damage, with consequent adverse effects on vision. Factors such as enhanced production of VEGF underlie the increased permeability of the BRB, and inhibition of VEGF is beneficial in humans and experimental models (Kaur et al., 2008; Jeganathan, 2011). In this vein, we have shown that ischemia pulses abrogate the increase in retinal VEGF levels induced by DR (Fernandez et al., 2011). Taken together, these results suggest that weekly ischemia pulses prevent retinal damage induced by experimental T1DM. However, the translational relevance of these results is limited by the fact that application of ischemia pulses started before the appearance of retinal changes provoked by diabetes. Therefore, we analyzed whether ischemia pulses could not only prevent but also reduce DR progression. For this purpose, we started the application of ischemia pulses at 6 weeks of diabetes onset, a time point in which a functional alteration is already evident. The delayed treatment resulted in a significant protection when compared with diabetic eyes submitted to a sham procedure, supporting that ischemic tolerance not only prevents but also restores the retinal function (Fernandez et al., 2011). On the other hand, we have shown thataxoglial alterations at the distal portion of the optic nerve could be the first structural change in the diabetic visual pathway (Fernandez et al., 2012a). Therefore, we analyzed the ability of ischemic conditioning on optic nerve axon protection against T1DM damage. In this sense, we demonstrated that ischemia pulses prevent a de fi cit in the anterograde transport from the retina to the superior colliculus, as well as an increase in astrocyte reactivity, ultraestructural myelin alterations, and altered morphology of oligodendrocyte lineage in the optic nerve distal portion at early stages of experimental diabetes (Fernandez et al., 2012b), which supports that ischemic tolerance protects optic nerve axonal function and structure against diabetic damage.

Ischemic tolerance on diabetic retinopathy associated to T2DM

In order to analyze the effect of ischemic tolerance on retinal damage associated with T2DM, adult male Wistar rats received a control diet or 30% sucrose in the drinking water, and 3 weeks after this treatment, animals were injected with vehicle or STZ (25 mg/kg) (Salido et al., 2012). Starting 3 weeks after vehicle or STZ, retinal ischemia was weekly induced by increasing IOP for 5 minutes in one eye, while control eyes were submitted to a sham procedure. At 12 weeks of treatment, animals that received a sucrose-enriched diet and STZ show signi fi cant differences in fasting and postprandial glycemia, and glucose, and insulin tolerance tests, as compared with control groups. Brief ischemia pulses in one eye and a sham procedure in the contralateral eye do not affect glucose metabolism in control or diabetic rats. Ischemic pulses reduce the decrease in the ERG a-wave, b-wave, and OP amplitude, and the increase in retinal VEGF levels in rats with experimental T2DM. Enhanced oxidative stress and infl ammatory signals play important roles in the pathogenesis of diabetes mellitus and its complications (Zheng and Kern, 2009; Mokini et al., 2010). A significant increase in retinal lipid peroxidation, TNFα levels, and NOS activity, as well as a decrease in catalase activity was observed in diabetic animals, which are reduced by ischemic tolerance (Salido et al., 2013).

Concluding remarks

These results indicate that ischemic tolerance protects the retina against damage induced by experimental T1DM and T2DM. Notably, the protection induced by ischemia pulses is independent from the glycemic pro fi le in both experimental models (Fernandez et al., 2011; Salido et al., 2013). Although different pathogenic mechanisms could be involved in retinal alterations induced by T1DM and T2DM, the application of ischemia pulses is effective in reducing retinal changes in both experimental models. The precise mechanisms responsible for the retinal protection induced by ischemia pulses remain to be established. Our results indicate that ischemic tolerance can behave as an antioxidant, antinitridergic, anti-in fl ammatory, and anti-VEGF therapy. Notwithstanding, the involvement of other mechanisms that have been implicated in retinal IPC (such as hypoxia-inducible factor-1 alpha and heme oxygenase-1 (Zhu et al., 2007), mitogen-activated protein kinase p38 (Dreixler et al., 2009a), protein kinase B/ Akt (Dreixler et al., 2009b), and mitochondrial K+/ATP channels (Roth et al., 2006), among others), cannot be excluded. Therefore, further studies to determine the mechanisms behind ischemic tolerance will provide a more complete picture of how neuroprotection is achieved in the context of retinal diabetic damage.

The relevance of these experimental studies to human DR is still an open question. Although care must to be taken when extrapolating data generated in rodents to humans, rodent retinas lacking the ability to develop bona fi de proliferative DR, exhibit almost all of the biochemical, pathophysiologic, and histopathologic features of background retinopathy. Many exogenously delivered chemical preconditioning agents (e.g., in fl ammatory cytokines, anesthetics, and metabolic inhibitors) can also induce ischemic tolerance, raising the hope that in the future, IPC and PostC could be pharmacologically mimickedin vivo(Gidday, 2006). Therefore, the present results support that induction of ischemic tolerance could constitute a fertile avenue for the development of new therapeutic strategies for DR treatment.

Barber AJ, Antonetti DA, Gardner TW; The Penn State Retina Research Group (2000) Altered expression of retinal occludin and glial fi brillary acidic protein in experimental diabetes. Invest Ophthalmol Vis Sci 41:3561-3568.

Barber AJ, Gardner TW, Abcouwer SF (2011) The signi fi cance of vascular and neural apoptosis to the pathology of diabetic retinopathy. Invest Ophthalmol Vis Sci 52:1156-1163.

Chan-Ling T, Stone J (1992) Degeneration of astrocytes in feline retinopathy of prematurity causes failure of the blood-retinal barrier. Invest Ophthalmol Vis Sci 33:2148-2159.

Coupland SG (1987) A comparison of oscillatory potential and pattern electroretinogram measures in diabetic retinopathy. Doc Ophthalmol 66:207-218.

Dreixler JC, Barone FC, Shaikh AR, Du E, Roth S (2009a) Mitogen-activated protein kinase p38alpha and retinal ischemic preconditioning. Exp Eye Res 89:782-790.

Dreixler JC, Hemmert JW, Shenoy SK, Shen Y, Lee HT, Shaikh AR, Rosenbaum DM, Roth S (2009b) The role of Akt/protein kinase B subtypes in retinal ischemic preconditioning. Exp Eye Res 88:512-521.

Du Y, Tang J, Li G, Berti-Mattera L, Lee CA, Bartkowski D, Gale D, Monahan J, Niesman MR, Alton G, Kern TS (2010) Effects of p38 MAPK inhibition on early stages of diabetic retinopathy and sensory nerve function. Invest Ophthalmol Vis Sci 51:2158-2164.

Fernandez DC, Bordone MP, Chianelli MS, Rosenstein RE (2009) Retinal neuroprotection against ischemia/reperfusion damage induced by postconditioning. Invest Ophthalmol Vis Sci 50:3922-3930.

Fernandez DC, Sande PH, Chianelli MS, Aldana Marcos HJ, Rosenstein RE (2011) Induction of ischemic tolerance protects the retina from diabetic retinopathy. Am J Pathol 178:2264-2274.

Fernandez DC, Pasquini LA, Dorfman D, Aldana Marcos HJ, Rosenstein RE (2012a) Early distal axonopathy of the visual pathway in experimental diabetes. Am J Pathol 180:303-313.

Fernandez DC, Pasquini LA, Dorfman D, Aldana Marcos HJ, Rosenstein RE (2012b) Ischemic conditioning protects from axoglial alterations of the optic pathway induced by experimental diabetes in rats. PLoS One 7:e51966.

Gardner TW (1995) Histamine. ZO-1 and increased blood-retinal barrier permeability in diabetic retinopathy. Trans Am Ophthalmol Soc 93:583-621.

Gardner TW, Lieth E, Khin SA, Barber AJ, Bonsall DJ, Lesher T, Rice K, Brennan WA Jr (1997) Astrocytes increase barrier properties and ZO-1 expression in retinal vascular endothelial cells. Invest Ophthalmol Vis Sci 38:2423-2427.

Gidday JM (2006) Cerebral preconditioning and ischaemic tolerance. Nat Rev Neurosci 7:437-448.

Holopigian K, Seiple W, Lorenzo M, Carr R (1992) A comparison of photopic and scotopic electroretinographic changes in early diabetic retinopathy. Invest Ophthalmol Vis Sci 33:2773-2780.

Jeganathan VS (2011) Anti-angiogenesis drugs in diabetic retinopathy. Curr Pharm Biotechnol 12:369-372.

Kaur C, Foulds WS, Ling EA (2008) Blood-retinal barrier in hypoxic ischaemic conditions: basic concepts, clinical features and management. Prog Retin Eye Res 27:622-647.

Kowluru RA, Chan PS (2007) Oxidative stress and diabetic retinopathy. Exp Diabetes Res 2007:43603-43614.

Lovasik JV, Kergoat H (1993) Electroretinographic results and ocular vascular perfusion in type 1 diabetes. Invest Ophthalmol Vis Sci 34:1731-1743.

Ma N, Hunt NH, Madigan MC, Chan-Ling T (1996) Correlation between enhanced vascular permeability, up-regulation of cellular adhesion molecules and monocyte adhesion to the endothelium in the retina during the development of fatal murine cerebral malaria. Am J Pathol 149:1745-1762.

Mokini Z, Marcovecchio ML, Chiarelli F (2010) Molecular pathology of oxidative stress in diabetic angiopathy: role of mitochondrial and cellular pathways. Diabetes Res Clin Pract 87:313-321.

Murry CE, Jennings RB, Reimer KA (1986) Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74:1124-1136.

Pignataro G, Meller R, Inoue K, Ordonez AN, Ashley MD, Xiong Z, Gala R, Simon RP (2008) In vivo and in vitro characterization of a novel neuroprotective strategy for stroke: ischemic postconditioning. J Cereb Blood Flow Metab 28:232-241.

Robinson R, Barathi VA, Chaurasia SS, Wong TY, Kern TS (2012) Update on animal models of diabetic retinopathy: from molecular approaches to mice and higher mammals. Dis Model Mech 5:444-456.

Roth S, Li B, Rosenbaum PS, Gupta H, Goldstein IM, Maxwell KM, Gidday JM (1998) Preconditioning provides complete protection against retinal ischemic injury in rats. Invest Ophthalmol Vis Sci 39:777-785.

Roth S, Dreixler JC, Shaikh AR, Lee KH, Bindokas V (2006) Mitochondrial potassium ATP channels and retinal ischemic preconditioning. Invest Ophthalmol Vis Sci 47:2114-2124.

Salido EM, de Zavalía N, Schreier L, De Laurentiis A, Rettori V, Chianelli M, Keller Sarmiento MI, Arias P, Rosenstein RE (2012) Retinal changes in an experimental model of early type 2 diabetes in rats characterized by non-fasting hyperglycemia. Exp Neurol 236:151-160.

Salido EM, Dorfman D, Bordone M, Chianelli MS, Sarmiento MI, Aranda M, Rosenstein RE (2013) Ischemic conditioning protects the rat retina in an experimental model of early type 2 diabetes. Exp Neurol 240:1-8.

Schnitzer J (1988) Astrocytes in the guinea pig, horse, and monkey retina: their occurrence coincides with the presence of blood vessels. Glia 1:74-89.

Shi Y, Hu FB (2014) The global implications of diabetes and cancer. Lancet 383:1947-1948.

Stitt AW, O’Neill CL, O’Doherty MT, Archer DB, Gardiner TA, Medina RJ (2011) Vascular stem cells and ischaemic retinopathies. Prog Retin Eye Res 30:149-166.

Szabad fi K, Pinter E, Reglodi D, Gabriel R (2014) Neuropeptides, trophic factors, and other substances providing morphofunctional and metabolic protection in experimental models of diabetic retinopathy. Int Rev Cell Mol Biol 311:1-121.

Wang JY, Shen J, Gao Q, Ye ZG, Yang SY, Liang HW, Bruce IC, Luo BY, Xia Q (2008) Ischemic postconditioning protects against global cerebral ischemia-reperfusion-induced injury in rats. Stroke 39:983-990.

Wei M, Ong L, Smith MT, Ross FB, Schmid K, Hoey AJ, Burstow D, Brown L (2003) The streptozotocin-diabetic rat as a model of the chronic complications of human diabetes. Heart Lung Circ 12:44-50.

Zhang SX, Ma JX, Sima J, Chen Y, Hu MS, Ottlecz A, Lambrou GN (2005) Genetic difference in susceptibility to the blood-retina barrier breakdown in diabetes and oxygen-induced retinopathy. Am J Pathol 166:313-321.

Zhang Y, Stone J (1997) Role of astrocytes in the control of developing retinal vessels. Invest Ophthalmol Vis Sci 38:1653-1666.

Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, Vinten-Johansen J (2003) Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 285:H579-588.

Zheng L, Kern TS (2009) Role of nitric oxide, superoxide, peroxynitrite and PARP in diabetic retinopathy. Front Biosci 14:3974-3987.

Zheng L, Du Y, Miller C, Gubitosi-Klug RA, Ball S, Berkowitz BA, Kern TS (2007) Critical role of inducible nitric oxide synthase in degeneration of retinal capillaries in mice with streptozotocin-induced diabetes. Diabetologia 50:1987-1996.

Zhu Y, Zhang Y, Ojwang BA, Brantley Jr MA, Gidday JM (2007) Longterm tolerance to retinal ischemia by repetitive hypoxic preconditioning: role of HIF-1alpha and heme oxygenase-1. Invest Ophthalmol Vis Sci 48:1735-1743.

Ruth E. Rosenstein, Departamento de Bioquímica Humana, Facultad de Medicina, /CEFyBO, UBA/CONICET. Paraguay 2155, 5°P, (1121), Buenos Aires, Argentina. ruthr@fmed.uba.ar.

10.4103/1673-5374.141782

http://www.nrronline.org/

Accepted: 2014-08-12